Day One Biopharmaceuticals (DAWN) EBIAT (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed EBIAT for 4 consecutive years, with -$21.3 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 67.62% to -$21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$107.3 million through Dec 2025, down 12.38% year-over-year, with the annual reading at -$107.3 million for FY2025, 12.38% down from the prior year.
- EBIAT for Q4 2025 was -$21.3 million at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
- The five-year high for EBIAT was $37.0 million in Q3 2024, with the low at -$65.7 million in Q4 2024.
- Average EBIAT over 4 years is -$33.4 million, with a median of -$37.2 million recorded in 2022.
- The sharpest move saw EBIAT surged 180.25% in 2024, then plummeted 588.04% in 2025.
- Over 4 years, EBIAT stood at -$40.1 million in 2022, then crashed by 35.91% to -$54.5 million in 2023, then decreased by 20.55% to -$65.7 million in 2024, then skyrocketed by 67.62% to -$21.3 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$21.3 million, -$19.7 million, and -$30.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.